Myelin Oligodendrocyte Glycoprotein 35-55, mouse, rat|CAS 149635-73-4|DC Chemicals

Cas No.:	149635-73-4
Chemical Name:	Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat
Synonyms:	L-Lysine,L-methionyl-L-a-glutamyl-L-valylglycyl-L-tryptophyl-L-tyrosyl-L-arginyl-L-seryl-L-prolyl-L-phenylalanyl-L-seryl-L-arginyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-tyrosyl-L-arginyl-L-asparaginylglycyl-;L-Lysine,L-methionyl-L-a-glutamyl-L-valylglycyl-L-tryptophyl-L-tyrosyl-L-arginyl-L-seryl-L-pro...;L-Lysine,L-methionyl-L-a-glutamyl-L-valylglycyl-L-tryptophyl-L-tyrosyl-L-arginyl-L-seryl-L-prolyl-L-phenylalanyl-L-seryl-L-ar;L-Lysine,L-methionyl-L-a-glutamyl-L-valylglycyl-L-tryptophyl-L-tyrosyl-L-arginyl-L-seryl-L-prolyl-L-phenylalanyl-L-seryl-L-arginyl-L-valyl-L-valyl-L-histidyl-L-leucyl-L-tyrosyl-L-arginyl-L-asparaginyl;MOG (35-55) (rat, mouse);MOG(35-55);Myelin Oligodendrocyte Glycoprotein (35-55) (mouse, rat);MyelinOligodendrocyteGlycoprotein(35-55)(mouse00rat);H-MEVGWYRSPFSRVVHLYRNGK-OH;MET-GLU-VAL-GLY-TRP-TYR-ARG-PRO-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS;MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS: MEVGWYRSPFSRVVHLYRNGK;MEVGWYRSPFSRVVHLYRNGK;Myelin Oligodendrocyte Glycoprotein Peptide: 35-55,rat,mouse;MOG (35-55), RAT;MOG (MOUSE, RAT);MOG (35-55), MOUSE, RAT;MOG (RAT, MOUSE, 35-55);MOG PEPTIDE (35-55) (RAT, MOUSE);MYELIN OLIGODENDROCYTE PROTEIN (35-55);Myelin Oligodendrocyte Glycoprotein (35-55);H-MET-GLU-VAL-GLY-TRP-TYR-ARG-SER-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH;(2S)-6-Amino-2-[[2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[;Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat
SMILES:	S(C([H])([H])[H])C([H])([H])C([H])([H])C([H])(C(N([H])C([H])(C([H])([H])C([H])([H])C(=O)O[H])C(N([H])C([H])(C([H])(C([H])([H])[H])C([H])([H])[H])C(N([H])C([H])([H])C(N([H])C([H])(C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12)C(N([H])C([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])C(N([H])C([H])(C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N/[H])/N([H])[H])C(N([H])C([H])(C([H])([H])O[H])C(N1C([H])([H])C([H])([H])C([H])([H])C1([H])C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])(C(N([H])C([H])([H])C(N([H])C([H])(C(=O)O[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H])=O)=O)C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N\[H])/N([H])[H])=O)C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C1=C([H])N([H])C([H])=N1)=O)C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])(C([H])([H])[H])C([H])([H])[H])=O)C([H])([H])C([H])([H])C([H])([H])N([H])/C(=N\[H])/N([H])[H])=O)C([H])([H])O[H])=O)C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O)=O)=O)=O)=O)=O)=O)=O)=O)N([H])[H]
Formula:	C₁₁₈H₁₇₇N₃₅O₂₉S
M.Wt:	2581.9501
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat is a minor component of CNS myelin. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat produces a relapsing-remitting neurological disease with extensive plaque-like demyelination. Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat induces strong T and B cell responses and is highly encephalitogenic[1][2][3].

References:

[1]. Ichikawa M, et al. Analysis of the fine B cell specificity during the chronic/relapsing course of a multiple sclerosis-like disease in Lewis rats injected with the encephalitogenic myelin oligodendrocyte glycoprotein peptide 35-55. J Immunol. 1996 Jul 15;157(2):919-26. [2]. Slavin A, et al. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity. 1998;28(2):109-20. [3]. Zhang GX, et al. T cell and antibody responses in remitting-relapsing experimental autoimmune encephalomyelitis in (C57BL/6 x SJL) F1 mice. J Neuroimmunol. 2004 Mar;148(1-2):1-10.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.